Europe Human Vaccine Adjuvants Market
No. of Pages: 113 | Report Code: BMIRE00030406 | Category: Life Sciences
No. of Pages: 113 | Report Code: BMIRE00030406 | Category: Life Sciences
The Europe human vaccine adjuvants market was valued at US$ 472.33 million in 2022 and is expected to reach US$ 1,338.00 million by 2030; it is estimated to register a CAGR of 13.9% from 2022 to 2030. Rising Trend of Personalized Vaccines Drives Europe Human Vaccine Adjuvants Market
Precision or personalized vaccines are a growing trend in the Europe human vaccine adjuvants market. These vaccines target specific genetic or molecular characteristics of a patient's disease, assisting the production of vaccines tailored to each patient's unique immune response. The technique can potentially improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders.
Adjuvants that can boost the immune response to these tailored vaccines are required to produce personalized vaccines. Adjuvants are essential in stimulating the immune system to develop a targeted and powerful response to the vaccine's specific antigens. As a result, there is an increasing demand for adjuvants that can effectively boost immune responses to personalized vaccines. In recent years, there has been a strong emphasis on R&D efforts to identify and create adjuvants that can effectively increase the immune response to personalized vaccines. For instance, in December 2022, Moderna and Merck announced mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab). Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared with KEYTRUDA alone. Regulatory bodies and healthcare organizations recognize personalized vaccines' potential for enhancing public health outcomes. For instance, in January 2023, BioNTech and the UK government signed a wide-reaching Memorandum of Understanding (MoU) to provide up to 10,000 patients with personalized mRNA cancer immunotherapies by 2030. This has increased funding for research and development initiatives in this field and measures to expedite regulatory routes for personalized vaccines and adjuvants. Thus, adjuvants that effectively improve the immune response to personalized vaccinations are increasingly being developed, enhancing vaccine efficacy and safety. This trend drives substantial innovation and investment in the Europe human vaccine adjuvants market.Europe Human Vaccine Adjuvants Market Overview
Germany is one of the top pharmaceutical markets in Europe and worldwide. According to Germany Trade & Invest (GTAI), it is the biggest pharmaceutical manufacturing location in the European Union, with approximately 600 pharmaceutical companies. According to GTAI, pharmaceutical production volume in Germany reached ~US$ 61.8 billion (~ 56.5 billion) in 2022. Further, the country ranks second in biopharmaceutical production after the US, which is attributed to favorable industrial infrastructure, a sustainably growing local chemicals industry, and highly qualified workforce availability. According to the same source, the pharmaceutical industry in Germany invested almost US$ 9.5 billion (~ 8.8 billion) in R&D in 2021, which is higher than the amounts invested in the R&D of any other industry. Catering to the largest population in Europe, Germany's healthcare sector is a highly attractive market with significant growth opportunities. A steady increase in life expectancy levels has led to a rise in chronic and age-related illnesses. An increase in the prevalence of infectious diseases is expected to fuel the demand for vaccinations. For instance, according to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, Germany has a population of 36.6 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Additionally, Germany has a high prevalence of hepatitis. Improved health awareness due to the prevalence of infectious diseases has further increased consumer demand for drugs, vaccines, and therapies. Thus, the demand for human vaccine adjuvants is growing rapidly in Germany with the flourishing pharmaceutical R&D landscape in pharmaceutical companies, alongside the increasing prevalence of infectious diseases.
Europe Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)
Strategic insights for the Europe Human Vaccine Adjuvants provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the Europe Human Vaccine Adjuvants refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
Get more information on this report Europe Human Vaccine Adjuvants Strategic Insights
Get more information on this report Europe Human Vaccine Adjuvants Report Scope
Report Attribute
Details
Market size in 2022
US$ 472.33 Million
Market Size by 2030
US$ 1,338.00 Million
Global CAGR (2022 - 2030)
13.9%
Historical Data
2020-2021
Forecast period
2023-2030
Segments Covered
By Type
By Application
By End User
Regions and Countries Covered
Europe
Market leaders and key company profiles
Get more information on this report Europe Human Vaccine Adjuvants Regional Insights
Get more information on this report
Europe Human Vaccine Adjuvants Market Segmentation
The Europe human vaccine adjuvants market is categorized into type, application, end user, and country.
Based on type, the Europe human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.
In terms of application, the Europe human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.
By end user, the Europe human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.
By country, the Europe human vaccine adjuvants market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe human vaccine adjuvants market share in 2022.
Creative Biolabs Inc, Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA, and SPI Pharma Inc are some of the leading companies operating in the Europe human vaccine adjuvants market.
1. Creative Biolabs Inc
2. Croda International Plc
3. CSL Ltd
4. Dynavax Technologies Corp
5. Novartis AG
6. Novavax Inc
7. Phibro Animal Health Corp
8. Seppic SA
9. SPI Pharma Inc
The Europe Human Vaccine Adjuvants Market is valued at US$ 472.33 Million in 2022, it is projected to reach US$ 1,338.00 Million by 2030.
As per our report Europe Human Vaccine Adjuvants Market, the market size is valued at US$ 472.33 Million in 2022, projecting it to reach US$ 1,338.00 Million by 2030. This translates to a CAGR of approximately 13.9% during the forecast period.
The Europe Human Vaccine Adjuvants Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Human Vaccine Adjuvants Market report:
The Europe Human Vaccine Adjuvants Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Human Vaccine Adjuvants Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Human Vaccine Adjuvants Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Human Vaccine Adjuvants Market
